SCHEMBL592091

SCHEMBL592091

COc1ccc2nccc(/C=C/C=O)c2n1

nearest known ligand 0.38

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 1/20 0.36
MAPK1 P28482 1/20 0.36
NPSR1 Q6W5P4 1/20 0.36
CDK4 P11802 2/20 0.34
CCND1 P24385 2/20 0.34
CCNB2 O95067 1/20 0.34
CDK1 P06493 1/20 0.34
CCNB1 P14635 1/20 0.34
CCNB3 Q8WWL7 1/20 0.34
MEN1 O00255 1/20 0.34
KMT2A Q03164 1/20 0.34
EGFR P00533 1/20 0.34
MAP4K4 O95819 1/20 0.33
ACVR1 Q04771 1/20 0.33
KCNH2 Q12809 2/20 0.33
PDE10A Q9Y233 4/20 0.33
NNMT P40261 1/20 0.33
PDE2A O00408 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL592092 1.00 KDM4E (0.36) KDM4EMAPK1NPSR1CDK4CCND1
SCHEMBL590647 0.84 CCR1 (0.42) KDM4EMAPK1NPSR1MEN1KMT2A
SCHEMBL590120 0.80 KDM4E (0.43) KDM4EMAPK1NPSR1MEN1KMT2A
SCHEMBL590121 0.80 KDM4E (0.43) KDM4EMAPK1NPSR1MEN1KMT2A
SCHEMBL592285 0.78 EGFR (0.36) KDM4EMAPK1NPSR1MEN1KMT2A
SCHEMBL3255262 0.78 TRPA1 (0.44) KDM4EMAPK1NPSR1MEN1KMT2A
SCHEMBL591870 0.78 KDM4E (0.35) KDM4EMAPK1NPSR1EGFRMAP4K4
SCHEMBL3255263 0.78 TRPA1 (0.44) KDM4EMAPK1NPSR1MEN1KMT2A
SCHEMBL591869 0.78 KDM4E (0.35) KDM4EMAPK1NPSR1EGFRMAP4K4
SCHEMBL2252676 0.75 KCNH2 (0.35) ACVR1KCNH2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2146987-B1 OXAZOLIDINONE ANTIBIOTIC DERIVATIVES ACTELION PHARMACEUTICALS LTD (CH) 2015-12-02 EP disclosed
US-8114867-B2 Oxazolidinone antibiotic derivatives ACTELION PHARMACEUTICALS LTD (CH) 2012-02-14 US disclosed
US-20100137290-A1 OXAZOLIDINONE ANTIBIOTIC DERIVATIVES ACTELION PHARMACEUTICALS LTD. (CH) 2010-06-03 US disclosed
EP-2146987-A2 OXAZOLIDINONE ANTIBIOTIC DERIVATIVES Actelion Pharmaceuticals Ltd. (CH) 2010-01-27 EP disclosed
WO-2008126024-A2 OXAZOLIDINONE ANTIBIOTIC DERIVATIVES ACTELION PHARMACEUTICALS LTD (CH) 2008-10-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100137290-A1 OXAZOLIDINONE ANTIBIOTIC DERIVATIVES OXA1L, XDH, CCNY KDM4E 1842/4885MAPK1 2466/4885NPSR1 1838/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.